Johnson & Johnson’s gene therapy for X-linked retinal pigmentosa did not meet the main vision goal of a pivotal study. J&J secured full rights to the program from gene therapy biotech MeiraGTx in 2023.
MeiraGTx’s gene therapy for Parkinson’s disease will enter Phase 3 testing under a new joint venture the biotech is forming with Hologen, a generative AI startup. The joint venture has up to $230 million in committed capital; MeiraGTx gets additional cash for its pipeline.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
In addition to meeting the main safety and tolerability goal, MeiraGTx Holdings’ gene therapy for Parkinson's disease also showed signs of efficacy. The one-time treatment is intended to reprogram dysfunctional brain circuits.